The emergence of a new COVID-19 variant, known as BA.3.2, has raised international health alerts. Despite the impact and lingering memory of the pandemic, this mutation does not currently represent a high-risk scenario.
According to the Centers for Disease Control and Prevention (CDC), this lineage has already been detected in at least 23 countries as of February, confirming its rapid global spread. Cases have also been identified in the United States.
ALSO READ: Israel and the US strike nuclear facilities in central Iran amid escalating conflict
These include two older adults with comorbidities who required hospitalization, as well as a minor who was treated on an outpatient basis. Health authorities have indicated that all patients have shown favorable recovery, reinforcing the idea that this variant is not, so far, associated with increased clinical severity.
New COVID-19 variant: What are its symptoms?
The defining feature of BA.3.2 is its ability to evade immune protection. Both the CDC and the World Health Organization (WHO) agree that this mutation could reduce the effectiveness of immunity acquired through vaccination or previous infections. Even so, the WHO continues to assess the public health risk as “low” and emphasizes that current vaccines remain effective in preventing severe illness.
As for symptoms, no significant differences have been identified compared to other Omicron variants. The most common signs include fever, dry cough, sore throat, fatigue, headache, nasal congestion, and muscle aches. In most cases, the illness presents as mild to moderate, particularly among vaccinated individuals.
The BA.3.2 variant was first identified in South Africa in November 2024 and has since spread to regions across Africa, Europe, Asia, and the Americas. Its evolution is part of the expected behavior of the virus, which continues to adapt and generate new mutations.
Specialists agree that while there is no cause for alarm, it remains essential to maintain epidemiological surveillance and reinforce preventive measures, especially given the possibility of new infections even among previously immunized individuals.
